anastrozole and azd2014

anastrozole has been researched along with azd2014 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	3 (100.00)	2.80

Authors

Authors	Studies
Abdeddaim, C; Arnaud, A; Augereau, P; Bazan, F; Chakiba, C; Chevalier-Place, A; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, P; Joly, F; Lancry-Lecomte, L; Marcel, V; Pautier, P; Pérol, D; Ray-Coquard, I; Treilleux, I; You, B	1
Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I	1

Trials

1 trial(s) available for anastrozole and azd2014

Article	Year
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. JAMA oncology, 2022, 07-01, Volume: 8, Issue:7 Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; MTOR Inhibitors; Phosphatidylinositol 3-Kinases; Pyrimidines; TOR Serine-Threonine Kinases	2022

Article

Year

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

JAMA oncology, 2022, 07-01, Volume: 8, Issue:7

Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; MTOR Inhibitors; Phosphatidylinositol 3-Kinases; Pyrimidines; TOR Serine-Threonine Kinases

2022

Other Studies

2 other study(ies) available for anastrozole and azd2014

Article	Year
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer. Cancer discovery, 2022, 07-06, Volume: 12, Issue:7 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; Nitriles; Pyrimidines; Triazoles	2022
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. Molecular oncology, 2023, Volume: 17, Issue:1 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Nitriles; Ribosomes; TOR Serine-Threonine Kinases; Triazoles	2023

Article

Year

Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.

Cancer discovery, 2022, 07-06, Volume: 12, Issue:7

Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; Nitriles; Pyrimidines; Triazoles

2022

Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.

Molecular oncology, 2023, Volume: 17, Issue:1

Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Nitriles; Ribosomes; TOR Serine-Threonine Kinases; Triazoles

2023